Skip to main content

Digibind Side Effects

Generic name: digoxin immune fab

Medically reviewed by Drugs.com. Last updated on May 4, 2020.

Note: This document contains side effect information about digoxin immune fab. Some of the dosage forms listed on this page may not apply to the brand name Digibind.

For the Consumer

Applies to digoxin immune fab: parenteral powder for injection

Side effects include:

Worsening of heart failure, hypokalemia, worsening of atrial fibrillation.

For Healthcare Professionals

Applies to digoxin immune fab: injectable powder for injection, injectable solution, intravenous powder for injection

General

The most common adverse events were worsening congestive heart failure, hypokalemia, and worsening atrial fibrillation.[Ref]

Cardiovascular

Very common (10% or more): Worsening congestive heart failure (13%)

Common (1% to 10%): Atrial fibrillation, transient postural hypertension[Ref]

Metabolic

Very common (10% or more): Hypokalemia (13%)[Ref]

Local

Common (1% to 10%): Phlebitis of the infusion-site vein[Ref]

Renal

Common (1% to 10%): Renal failure[Ref]

Renal failure occurred in one patient and was determined to be likely due to loss of digoxin inotropic support in combination with the patients underlying medical condition.[Ref]

Respiratory

Pulmonary edema and bilateral pleural effusion occurred in one patient and was determined to be likely due to loss of digoxin inotropic support in combination with the patients underlying medical condition.[Ref]

Common (1% to 10%): Pulmonary edema, bilateral pleural effusion[Ref]

More about Digibind (digoxin immune fab)

Consumer resources

Other brands
DigiFab

Professional resources

Related treatment guides

References

1. "Product Information. DigiFab (digoxin immune FAB)." BTG International Inc, West Conshohocken, PA.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.